Bayer is making a big bet on gene therapy with the acquisition of North Carolina-based Asklepios BioPharmaceutical (AskBio).

San Diego-based Retrophin is buying Orphan Technologies for $90 million in cash up front and up to $427 million in milestone payments.

Corbus Pharmaceuticals intends to restructure the company’s workforce and reallocate capital toward specific clinical and preclinical programs.

A vaccine against Covid-19 may be ready by year-end, the head of the World Health Organization (WHO) said, without elaborating.

XtalPi Inc., an AI-based pharmaceutical technology company with an AI-powered platform that twins with existing R&D pipelines, raised an additional $318.8 million through a Series C financing round to bring drug development into the future.

Somerville, Massachusetts-based Finch Therapeutics closed a $90 million Series D financing, with plans to use the funds to advance the company’s lead candidate CP101 for recurrent C. difficile infection through the final stages of clinical development and regulatory submission.

iBio Inc. is developing a decoy molecule as a therapeutic against SARS-CoV-2.

Takeda Pharmaceutical opened a new 24,000-square-foot R&D cell therapy manufacturing facility in Boston at the site of the company’s R&D headquarters.

Roche aims to defend the company’s multiple sclerosis (MS) franchise from rivals Novartis and Sanofi with new studies of the Swiss drugmaker’s $4 billion-per-year Ocrevus product and advanced trials of the experimental medicine fenebrutinib.

Shares of Akcea Therapeutics were up more than 60 percent in trading after majority owner Ionis Pharmaceuticals announced it will acquire all outstanding shares of the company, which amounts to about 24 percent of available stock for $18.50 per share.